Lucio Vilar1, Luciana A Naves, Márcio C Machado, Marcello D Bronstein. 1. Division of Endocrinology, Hospital das Clínicas, Federal University of Pernambuco, Rua Clovis Silveira Barros, 84/1202, Boa Vista, Recife, CEP 50.050-270, Brazil, lvilarf@gmail.com.
Abstract
INTRODUCTION: There has been growing interest on medical therapy for the management of Cushing's disease (CD), particularly in cases of persistent or recurrent hypercortisolism. Ketoconazole, an inhibitor of adrenal steroidogenesis, is the most widely used drug, whereas cabergoline and pasireotide are the most promising centrally acting agents. The main purpose of this review article is to highlight the options of medical treatment for CD, with a special emphasis on combination therapies, a topic that has only been addressed by a limited number of studies. CONCLUSIONS: According to the results of these studies, combination therapies involving medications with additive or synergistic effects on ACTH and cortisol secretion seem quite attractive as they yield higher probability of longterm control of the hypercortisolism at lower doses, a lower incidence of side-effects, and possibly a lower rate of treatment escapes. Currently, ketoconazole, cabergoline, and pasireotide are the best drugs to be prescribed in combination.
INTRODUCTION: There has been growing interest on medical therapy for the management of Cushing's disease (CD), particularly in cases of persistent or recurrent hypercortisolism. Ketoconazole, an inhibitor of adrenal steroidogenesis, is the most widely used drug, whereas cabergoline and pasireotide are the most promising centrally acting agents. The main purpose of this review article is to highlight the options of medical treatment for CD, with a special emphasis on combination therapies, a topic that has only been addressed by a limited number of studies. CONCLUSIONS: According to the results of these studies, combination therapies involving medications with additive or synergistic effects on ACTH and cortisol secretion seem quite attractive as they yield higher probability of longterm control of the hypercortisolism at lower doses, a lower incidence of side-effects, and possibly a lower rate of treatment escapes. Currently, ketoconazole, cabergoline, and pasireotide are the best drugs to be prescribed in combination.
Authors: Richard A Feelders; Christiaan de Bruin; Alberto M Pereira; Johannes A Romijn; Romana T Netea-Maier; Ad R Hermus; Pierre M Zelissen; Ramona van Heerebeek; Frank H de Jong; Aart-Jan van der Lely; Wouter W de Herder; Leo J Hofland; Steven W Lamberts Journal: N Engl J Med Date: 2010-05-13 Impact factor: 91.245
Authors: Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao Journal: J Clin Endocrinol Metab Date: 2008-10-28 Impact factor: 5.958
Authors: L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein Journal: J Endocrinol Invest Date: 2008-05 Impact factor: 4.256
Authors: Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller Journal: J Clin Endocrinol Metab Date: 2013-12-11 Impact factor: 5.958
Authors: M Boscaro; J Bertherat; J Findling; M Fleseriu; A B Atkinson; S Petersenn; J Schopohl; P Snyder; G Hughes; A Trovato; K Hu; M Maldonado; B M K Biller Journal: Pituitary Date: 2014-08 Impact factor: 4.107
Authors: Lucio Vilar; José Luciano Albuquerque; Ruy Lyra; Erik Trovão Diniz; Frederico Rangel Filho; Patrícia Gadelha; Ana Carolina Thé; George Robson Ibiapina; Barbara Sales Gomes; Vera Santos; Maíra Melo da Fonseca; Karoline Frasão Viana; Isis Gabriella Lopes; Douglas Araújo; Luciana Naves Journal: Int J Endocrinol Date: 2016-02-29 Impact factor: 3.257